Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
25 nov. 2020 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT)(“Lixte” or the “Company”), today announced the pricing of its underwritten public offering of...
The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
18 août 2020 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to...
Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
21 juil. 2020 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, July 21, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) today announced the appointment of Dr. James Miser as its Chief Medical Officer commencing...
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
30 avr. 2020 10h30 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the National Cancer Institute (NCI) and National Institute of...
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
04 déc. 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...
The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
06 août 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it signed a clinical trial agreement with the Spanish Sarcoma Group (Grupo...
The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
06 août 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it signed a clinical trial agreement with the Spanish Sarcoma Group (Grupo...
First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
18 juil. 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, July 18, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and...
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
25 juin 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, June 25, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that a group of neuroscientists in China and Japan reported that Lixte’s lead clinical...
Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
15 mai 2019 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 15, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the opening of a pharmacologic study of the ability of its lead clinical compound,...